Effectiveness and safety of age-based dosing of abrocitinib in children and adolescents with moderate to severe atopic dermatitis: A two-center, prospective real-world study in China.

ABSTRACT: Abrocitinib have been approved for patients with moderate to severe atopic dermatitis (AD), but its effectiveness and safety in adolescents, especially children is not established in both clinical trial and real-world studies. We aimed to analyze real-world data of abrocitinib in the treatment of children and adolescents. We prospectively enrolled children and adolescents with moderate to severe AD from 2 centers, who were stratified based on age groups (<6 years, 6-11 years, 12-17 years) and treated with oral abrocitinib at dosages of 25, 50, or 100 mg daily accordingly. The study assessed various parameters, including the eczema area and severity index (EASI), scoring of atopic dermatitis, investigator's global assessment, numerical rating scale-itch, sleep-loss scores, children dermatol

SUBMITTER: Liang J 

PROVIDER: S-EPMC12014022 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature